Dr. Nghiem on Pembrolizumab for Advanced Merkel Cell Carcinoma

Video

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine discusses a phase II trial investigating the PD-1 blockade pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses a phase II trial investigating PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).

Adults with advanced, unresectable MCC, good performance status, and those who were not immune suppressed or did not have autoimmune disease were eligible for the trial. Pembrolizumab was administered at 2 mg/kg every 3 weeks. At the time of analysis, which was performed after 12-weeks of treatment, 24 patients had received pembrolizumab and 14 patients had been scanned for signs of disease, explains Nghiem.

Of the 14 evaluable patients, 10 responded to pembrolizumab; representing a 71% response rate, according to Nghiem. These responses consisted of 1 complete response (CR), 1 unconfirmed CR, 4 partial responses (PR), 2 unconfirmed PRs, and 2 progressions. While this data is still early, these results are very promising, especially in such a rare and difficult-to-treat disease, says Nghiem.

Although analysis of PD-L1 expression is still ongoing, Merkel polyomavirus-specific T cells, which are often found in patients with MCC, commonly express inhibitory coreceptors, such as PD-1. Additionally, MCC often expresses PD-L1, suggesting that this rare disease could be highly vulnerable to PD-1 inhibition.

<<<

View more from the 2015 European Cancer Congress

Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
© 2025 MJH Life Sciences

All rights reserved.